FAST LINK SHOW NOTES
PODCAST 49 - Part 1
1.
Douglas R. Galasko, MD Bio
UC San Diego Health2.
FDA clears first blood test used in diagnosing Alzheimer’s diseaseFDA.gov3.
Alzheimer’s Association - Alzheimer’s disease facts and figuresAlz.org4.
Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control studyPubMed5.
Clinical and biomarker changes in dominantly inherited Alzheimer's diseasePubMed6.
Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer’s disease: A longitudinal studyThe Lancet7.
A systematic review on the evidence of misdiagnosis in dementia and its Impact on accessing dementia carePubMed8.
Biomarkers in Alzheimer's disease: role in early and differential diagnosis and recognition of atypical variantsAlzheimer's Research & Therapy9.
FDA converts novel Alzheimer’s disease treatment to traditional approvalFDA.gov10.
Performance of plasma phosphorylated tau 181 and 217 in the communityPubMed11.
Discriminative accuracy of plasma phospho-tau 217 for Alzheimer’s disease vs other neurodegenerative disordersJAMA Network12.
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer’s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance studyThe Lancet13.
Plasma phosphorylated tau 217 in preclinical Alzheimer’s diseasePubMed14.
Plasma amyloid β-peptide 1–42 and incipient Alzheimer's diseasePubMed15.
Prediction of longitudinal cognitive decline in preclinical Alzheimer disease using plasma biomarkersJAMA Network16.
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applicationsMolecular Neurodegeneration17.
Fujirebio receives marketing clearance for Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic test as an aid to identify patients with amyloid pathology associated with Alzheimer's diseaseFujirebioPODCAST 50 - Part 2
1.
Francesca I. De Simone, PhD Bio
LinkedIn2.
FDA clears first blood test used in diagnosing Alzheimer’s diseaseFDA.gov3.
Alzheimer’s Association - Alzheimer’s disease facts and figuresAlz.org4.
Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control studyPubMed5.
Clinical and biomarker changes in dominantly inherited Alzheimer's diseasePubMed6.
Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer’s disease: A longitudinal studyThe Lancet7.
A systematic review on the evidence of misdiagnosis in dementia and its Impact on accessing dementia carePubMed8.
Biomarkers in Alzheimer's disease: role in early and differential diagnosis and recognition of atypical variantsAlzheimer's Research & Therapy9.
FDA converts novel Alzheimer’s disease treatment to traditional approvalFDA.gov10.
Performance of plasma phosphorylated tau 181 and 217 in the communityPubMed11.
Discriminative accuracy of plasma phospho-tau 217 for Alzheimer’s disease vs other neurodegenerative disordersJAMA Network12.
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer’s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance studyThe Lancet13.
Plasma phosphorylated tau 217 in preclinical Alzheimer’s diseasePubMed14.
Plasma amyloid β-peptide 1–42 and incipient Alzheimer's diseasePubMed15.
Prediction of longitudinal cognitive decline in preclinical Alzheimer disease using plasma biomarkersJAMA Network16.
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applicationsMolecular Neurodegeneration17.
Fujirebio receives marketing clearance for Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic test as an aid to identify patients with amyloid pathology associated with Alzheimer's diseaseFujirebioMEDICAL MYSTERY CASESOMG Medical HistoryCME/CESlide CenterCardiologyCOVID-19DiabetesDisparityGastroenterologyGynecologyInfectious DiseasesNephrologyNeurologyOpioid ReductionOrphan DiseasesSpecial Episodes
© Medavera 2025 All rights reserved.
The content on this website is protected by copyright. Medavera, Inc. consents to the private use and non-commercial use of its podcasts for educational purposes. If you are interested in modifying or adapting Medavera’s podcasts for educational or commercial use, please Contact Us .